Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-806-1074
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.22 million
Profitability
Miscellaneous
Employees82
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Chimerix (NASDAQ:CMRX) Frequently Asked Questions
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
How were Chimerix's earnings last quarter?
Chimerix Inc (NASDAQ:CMRX) issued its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.18. The biopharmaceutical company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.30 million. Chimerix had a negative return on equity of 38.70% and a negative net margin of 729.02%. View Chimerix's Earnings History.
When is Chimerix's next earnings date?
What price target have analysts set for CMRX?
3 equities research analysts have issued 12-month target prices for Chimerix's shares. Their predictions range from $2.00 to $7.00. On average, they anticipate Chimerix's share price to reach $4.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for Chimerix.
What is the consensus analysts' recommendation for Chimerix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.
Has Chimerix been receiving favorable news coverage?
Media coverage about CMRX stock has trended negative recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Chimerix earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Chimerix.
Are investors shorting Chimerix?
Chimerix saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 622,600 shares, a decrease of 31.8% from the July 31st total of 912,900 shares. Based on an average trading volume of 382,200 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.4% of the company's shares are sold short. View Chimerix's Current Options Chain.
Who are some of Chimerix's key competitors?
Some companies that are related to Chimerix include Flexion Therapeutics (FLXN), Akebia Therapeutics (AKBA), DiaMedica Therapeutics (DMCAF), Milestone Pharmaceuticals (MIST), Myovant Sciences (MYOV), Lannett (LCI), Akero Therapeutics (AKRO), Retrophin (RTRX), Achillion Pharmaceuticals (ACHN), Basilea Pharmaceutica (BPMUF), Viking Therapeutics (VKTX), Akorn (AKRX), Urogen Pharma (URGN), ImmunoGen (IMGN) and Aptorum Group (APM).
What other stocks do shareholders of Chimerix own?
Who are Chimerix's key executives?
Chimerix's management team includes the folowing people:
- Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
- Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
- Mr. Michael A. Sherman, CEO & Pres (Age 53)
- Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
- Dr. Randall Lanier Ph.D., Chief Science Officer
Who are Chimerix's major shareholders?
Chimerix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.63%), Morgan Stanley (4.10%), Vanguard Group Inc. (3.83%), Renaissance Technologies LLC (3.45%), Citadel Advisors LLC (1.87%) and Parametric Portfolio Associates LLC (1.26%). Company insiders that own Chimerix stock include Ernest Mario, Fred A Middleton, Linda M Richardson, M Michelle Berrey, Martha J Demski and Michael A Sherman. View Institutional Ownership Trends for Chimerix.
Which major investors are selling Chimerix stock?
CMRX stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., JPMorgan Chase & Co., Panagora Asset Management Inc., Price T Rowe Associates Inc. MD, RBF Capital LLC, Invesco Ltd., AXA and M&T Bank Corp. View Insider Buying and Selling for Chimerix.
Which major investors are buying Chimerix stock?
CMRX stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Morgan Stanley, Nuveen Asset Management LLC, Vanguard Group Inc., Renaissance Technologies LLC, Point72 Asset Management L.P., BlackRock Inc. and Jacobs Levy Equity Management Inc.. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, M Michelle Berrey, Martha J Demski and Michael A Sherman. View Insider Buying and Selling for Chimerix.
How do I buy shares of Chimerix?
Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Chimerix's stock price today?
One share of CMRX stock can currently be purchased for approximately $2.44.
How big of a company is Chimerix?
Chimerix has a market capitalization of $149.50 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.View Additional Information About Chimerix.
What is Chimerix's official website?
How can I contact Chimerix?
Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]
MarketBeat Community Rating for Chimerix (NASDAQ CMRX)
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
